Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11,128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer.
Jhaveri K, Juric D, Yap YS, Cresta S, Layman RM, Duhoux FP, Terret C, Takahashi S, Huober J, Kundamal N, Sheng Q, Balbin A, Ji Y, He W, Crystal A, De Vita S, Curigliano G. Jhaveri K, et al. Among authors: takahashi s. Clin Cancer Res. 2021 Nov 1;27(21):5760-5770. doi: 10.1158/1078-0432.CCR-21-1095. Epub 2021 Aug 25. Clin Cancer Res. 2021. PMID: 34433648 Free PMC article.
Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma.
Terui Y, Mishima Y, Sugimura N, Kojima K, Sakurai T, Mishima Y, Kuniyoshi R, Taniyama A, Yokoyama M, Sakajiri S, Takeuchi K, Watanabe C, Takahashi S, Ito Y, Hatake K. Terui Y, et al. Among authors: takahashi s. Clin Cancer Res. 2009 Apr 1;15(7):2523-30. doi: 10.1158/1078-0432.CCR-08-1403. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276251
Prospective randomized phase II study determines the clinical usefulness of genetic biomarkers for sensitivity to primary chemotherapy with paclitaxel in breast cancer.
Ito Y, Nagasaki K, Miki Y, Iwase T, Akiyama F, Matsuura M, Horii R, Makita M, Tokudome N, Ushijima M, Yoshimoto M, Takahashi S, Noda T, Hatake K. Ito Y, et al. Among authors: takahashi s. Cancer Sci. 2011 Jan;102(1):130-6. doi: 10.1111/j.1349-7006.2010.01740.x. Epub 2010 Sep 30. Cancer Sci. 2011. PMID: 20880335 Free article. Clinical Trial.
Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.
Araki K, Fukada I, Horii R, Takahashi S, Akiyama F, Iwase T, Ito Y. Araki K, et al. Among authors: takahashi s. Breast Cancer Res Treat. 2014 Nov;148(1):197-209. doi: 10.1007/s10549-014-3148-7. Epub 2014 Oct 1. Breast Cancer Res Treat. 2014. PMID: 25270122
Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer.
Tamura K, Kodaira M, Shimizu C, Yonemori K, Yunokawa M, Shimomura A, Kobayashi T, Nakano K, Tomomatsu J, Ito Y, Tanaka J, Kuriki H, Gu Z, Takahashi S. Tamura K, et al. Among authors: takahashi s. Cancer Sci. 2018 May;109(5):1592-1601. doi: 10.1111/cas.13561. Epub 2018 Mar 31. Cancer Sci. 2018. PMID: 29500843 Free PMC article. Clinical Trial.
11,128 results
You have reached the last available page of results. Please see the User Guide for more information.